Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05593328 · ClinicalTrials.gov registry record · Phase 2
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
A Phase 2 study, sponsored by Cardiff Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT05593328 is a Phase 2 study that has completed, run by Cardiff Oncology. The registered enrollment target is 23 participants.
The verdict
NCT05593328, a Phase 2 study, has completed, sponsored by Cardiff Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil \[5-FU\], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed metastatic and/or unresectable colorectal cancer (CRC) in participants with a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation who have progressed on an oxaliplatin/fluoropyrimidinebased regimen in the first-line setting.
Interventions
- DRUG Bevacizumab
- DRUG FOLFIRI
- DRUG Onvansertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-03-17 |
| Est. Completion | 2024-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05593328
The ClinicalTrials.gov registry entry for NCT05593328 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardiff Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT05593328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05593328 about?
NCT05593328 is a clinical study titled "Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation". The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil \[5-FU\], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed metastatic and/or unresectable colorectal cancer (CRC...
What is the current status of trial NCT05593328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2023-03-17. Estimated completion is 2024-12-09.
What interventions are being tested in trial NCT05593328?
The interventions under investigation include: Bevacizumab (DRUG), FOLFIRI (DRUG), Onvansertib (DRUG).
Who is sponsoring clinical trial NCT05593328?
This trial is sponsored by Cardiff Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.